| abstract |
The present invention provides methods for treating refractory chronic lymphocytic leukemia (CLL) with a CDK inhibitor. In one embodiment refractory CLL patients to be treated with the CDK inhibitor, dinaciclib, are selected on the basis of presence or absence of the 17p deletion. In another embodiment the invention is a pharmaceutical preparation comprising dinaciclib to treat refractory CLL patients having del 17p. |